OGI vs. CPH, CRDL, HLS, GUD, ACB, VHI, DR, KSI, FRX, and QIPT
Should you be buying Organigram stock or one of its competitors? The main competitors of Organigram include Cipher Pharmaceuticals (CPH), Cardiol Therapeutics (CRDL), HLS Therapeutics (HLS), Knight Therapeutics (GUD), Aurora Cannabis (ACB), Vitalhub (VHI), Medical Facilities (DR), kneat.com (KSI), Fennec Pharmaceuticals (FRX), and Quipt Home Medical (QIPT). These companies are all part of the "medical" sector.
Organigram (TSE:OGI) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, community ranking, risk and institutional ownership.
Organigram has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Cipher Pharmaceuticals has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.
Organigram currently has a consensus target price of C$3.85, indicating a potential upside of 60.42%. Cipher Pharmaceuticals has a consensus target price of C$8.00, indicating a potential downside of 13.51%. Given Organigram's higher probable upside, research analysts clearly believe Organigram is more favorable than Cipher Pharmaceuticals.
Cipher Pharmaceuticals has lower revenue, but higher earnings than Organigram. Organigram is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cipher Pharmaceuticals had 2 more articles in the media than Organigram. MarketBeat recorded 3 mentions for Cipher Pharmaceuticals and 1 mentions for Organigram. Cipher Pharmaceuticals' average media sentiment score of 1.20 beat Organigram's score of 0.00 indicating that Cipher Pharmaceuticals is being referred to more favorably in the news media.
Cipher Pharmaceuticals received 132 more outperform votes than Organigram when rated by MarketBeat users. Likewise, 62.68% of users gave Cipher Pharmaceuticals an outperform vote while only 44.23% of users gave Organigram an outperform vote.
Cipher Pharmaceuticals has a net margin of 96.32% compared to Organigram's net margin of -153.80%. Cipher Pharmaceuticals' return on equity of 28.19% beat Organigram's return on equity.
9.0% of Organigram shares are owned by institutional investors. Comparatively, 1.1% of Cipher Pharmaceuticals shares are owned by institutional investors. 27.3% of Organigram shares are owned by insiders. Comparatively, 44.5% of Cipher Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Cipher Pharmaceuticals beats Organigram on 13 of the 18 factors compared between the two stocks.
Get Organigram News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OGI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organigram Competitors List
Related Companies and Tools
